文献速递前列腺癌

晚期前列腺癌男性口服雄激素信号抑制剂后按既存心血管合并症分层的死亡与住院风险

Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.
PubMed 文献 · Eur Urol · 2019-08-13

基于监测、流行病学和最终结果-医疗保险关联数据库的回顾性人群研究,纳入使用醋酸阿比特龙(AA)或恩扎卢胺(ENZ)的前列腺癌患者2845例与1031例,67%有至少一种既存心血管疾病(CVD)。与无既存CVD者相比,有1至2种既存CVD与6个月死亡率升高16%相关(RR=1.16,95%CI 1.00-1.36),有3种及以上CVD者风险进一步升高(RR=1.56,95%CI 1.29-1.88);生存差异多发生在治疗前6个月内,且与使用AA还是ENZ无关。

要点

  • 有1至2种既存CVD者6个月死亡率较无CVD者升高16%(RR=1.16,95%CI 1.00-1.36)。
  • 有3种及以上既存CVD者6个月死亡率较无CVD者进一步升高(RR=1.56,95%CI 1.29-1.88)。
  • CVD相关死亡风险与使用AA还是ENZ无关。

核心结论

  • 接受AA或ENZ治疗的老年前列腺癌患者中,有既存CVD者短期死亡率高于无CVD的相似患者。
  • CVD相关的死亡率与接受AA还是ENZ无关。

研究设计与样本

  • 基于监测、流行病学和最终结果-医疗保险关联数据库的回顾性人群研究。
  • 纳入使用AA或ENZ的前列腺癌患者,AA组2845例,ENZ组1031例。
  • 主要终点为6个月全因死亡率,采用改良泊松回归模型分析校正混杂因素和合并症后的相对风险(RR)。

主要发现

  • 纳入患者中67%有至少一种既存CVD。
  • 与无既存CVD者相比,有1至2种既存CVD与6个月死亡率升高16%相关(RR=1.16,95%CI 1.00-1.36)。
  • 与无既存CVD者相比,有3种及以上既存CVD者6个月死亡率风险进一步升高(RR=1.56,95%CI 1.29-1.88)。
  • 有既存CVD患者的生存差异多发生在治疗前6个月内。

临床怎么用

  • 作者建议在制定治疗决策和监测潜在副作用过程中,由包括心脏科医生在内的多学科团队对有既存CVD的患者进行评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Elderly patients (≥65yr) with advanced prostate cancer and cardiovascular disease (CVD) conditions are often excluded from clinical trials of abiraterone acetate (AA) or enzalutamide (ENZ). Consequently, little is known about the effects of these medications on these vulnerable patients. OBJECTIVE: To assess the short-term outcomes of AA and ENZ in patients with pre-existing CVDs. DESIGN, SETTING, AND PARTICIPANTS: A population-based retrospective study. The Surveillance, Epidemiology, and End Results-Medicare-linked database was used to identify prostate cancer patients using AA or ENZ. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was 6-mo all-cause mortality, analyzed using modified Poisson regression modeling of relative risk (RR) adjusted for confounders and comorbidities. RESULTS AND LIMITATIONS: Among eligible patients (2845 with AA and 1031 with ENZ), 67% had at least one pre-existing CVD. Compared with those without pre-existing CVDs, having one to two pre-existing CVDs was associated with 16% higher 6-mo mortality (RR=1.16, 95% confidence interval [CI]: 1.00-1.36), and the risk increased further among those having three or more CVDs (RR=1.56, 95% CI: 1.29-1.88). Most of the differences in survival of patients with pre-existing CVD condition occurred within the first 6mo of treatment. CONCLUSIONS: After treatment with AA or ENZ, elderly prostate cancer patients with pre-existing CVDs experienced higher short-term mortality than otherwise similar patients without CVDs. Mortality associated with CVDs did not depend on having received AA versus ENZ. PATIENT SUMMARY: Patients with pre-existing cardiovascular diseases (CVDs) experienced higher short-term mortality after abiraterone acetate or enzalutamide than those without pre-existing CVDs. It is recommended that a multidisciplinary team, including a cardiologist, evaluate patients having pre-existing CVDs in the process of making treatment decisions and monitoring potential side effects.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Lu-Yao G, Nikita N, Keith SW, et al. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol. 2019. PMID: 31420248. doi:10.1016/j.eururo.2019.07.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。